FDA Adverse Event Malfunction Summary report: N

ACTIVA

MDR report key: 7422374 · Received April 11, 2018

Report

Report Number
3007566237-2018-01056
Event Type
Malfunction
Date Received
April 11, 2018
Date of Event
January 13, 2018
Report Date
April 11, 2018
Manufacturer
MEDTRONIC NEUROMODULATION
Product Code
MHY
PMA / PMN Number
P960009
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
UK
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE REPORTED AGE REFLECTS THE AVERAGE AGE OF THE PATIENTS REPORTED IN THE LITERATURE ARTICLE. THE REPORTED SEX REFLECTS THAT OF THE MAJORITY OF THE PATIENTS REPORTED IN THE LITERATURE ARTICLE. PLEASE NOTE THAT THIS DATE IS BASED OFF OF THE DATE OF ACCEPTANCE OF THE ARTICLE AS THE EVENT DATES WERE NOT PROVIDED IN THE PUBLISHED LITERATURE. THE DEVICE WAS USED FOR AN OFF LABEL INDICATION; IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

Description of Event or Problem · 1

AKRAM, H., DAYAL, V., MAHLKNECHT, P., GEORGIEV, D., HYAM, J., FOLTYNIE, T., . . . ZRINZO, L. (2018). CONNECTIVITY DERIVED THALAMIC SEGMENTATION IN DEEP BRAIN STIMULATION FOR TREMOR. NEUROIMAGE: CLINICAL, 18, 130-142. DOI:10.1016/J.NICL.2018.01.008 SUMMARY: THE VENTRAL INTERMEDIATE NUCLEUS (VIM) OF THE THALAMUS IS AN ESTABLISHED SURGICAL TARGET FOR STEREOTACTIC ABLATION AND DEEP BRAIN STIMULATION (DBS) IN THE TREATMENT OF TREMOR IN PARKINSON'S DISEASE (PD) AND ESSENTIAL TREMOR (ET). IT IS CENTRALLY PLACED ON A CEREBELLO-THALAMO CORTICAL NETWORK CONNECTING THE PRIMARY MOTOR CORTEX, TO THE DENTATE NUCLEUS OF THE CONTRALATERAL CEREBELLUM THROUGH THE DENTATO-RUBRO-THALAMIC TRACT (DRT). THE VIM IS NOT READILY VISIBLE ON CONVENTIONAL MR IMAGING, SO IDENTIFYING THE SURGICAL TARGET TRADITIONALLY INVOLVED INDIRECT TARGETING THAT RELIES ON ATLAS-DEFINED COORDINATES. UNFORTUNATELY, THIS APPROACH DOES NOT FULLY ACCOUNT FOR INDIVIDUAL VARIABILITY AND REQUIRES SURGERY TO BE PERFORMED WITH THE PATIENT AWAKE TO ALLOW FOR INTRAOPERATIVE TARGETING CONFIRMATION. THE AIM OF THIS STUDY IS TO IDENTIFY THE VIM AND THE DRT USING PROBABILISTIC TRACTOGRAPHY IN PATIENTS THAT WILL UNDERGO THALAMIC DBS FOR TREMOR. FOUR MALE PATIENTS WITH TREMOR DOMINANT PD AND FIVE PATIENTS (THREE FEMALE) WITH ET UNDERWENT HIGH ANGULAR RESOLUTION DIFFUSION IMAGING (HARDI) (128 DIFFUSION DIRECTIONS, 1.5MM ISOTROPIC VOXELS AND B VALUE=1500) PREOPERATIVELY. PATIENTS RECEIVED VIM-DBS USING AN MR IMAGE GUIDED AND MR IMAGE VERIFIED APPROACH WITH INDIRECT TARGETING. POSTOPERATIVELY, USING PARALLEL GRAPHICAL PROCESSING UNIT (GPU) PROCESSING, THALAMIC AREAS WITH THE HIGHEST DIFFUSION CONNECTIVITY TO THE PRIMARY MOTOR AREA (M1), SUPPLEMENTARY MOTOR AREA (SMA), PRIMARY SENSORY AREA (S1) AND CONTRALATERAL DENTATE NUCLEUS WERE IDENTIFIED. ADDITIONALLY, VOLUME OF TISSUE ACTIVATION (VTA) CORRESPONDING TO ACTIVE DBS CONTACTS WERE MODELLED. RESPONSE TO TREATMENT WAS DEFINED AS 40% REDUCTION IN THE TOTAL FAHN-TOLOSA-MARTIN TREMOR RATING SCORE (FTMTRS) WITH DBS-ON, ONE YEAR FROM SURGERY. THREE OUT OF NINE PATIENTS HAD A SUBOPTIMAL, LONG-TERM RESPONSE TO TREATMENT. THE SEGMENTED THALAMIC AREAS CORRESPONDED WELL TO ANATOMICALLY KNOWN COUNTERPARTS IN THE VENTROLATERAL (VL) AND VENTROPOSTERIOR (VP) THALAMUS. THE DENTATE-THALAMIC AREA, LAY WITHIN THE M1-THALAMIC AREA IN A VENTRAL AND LATERAL LOCATION. STREAMLINES CORRESPONDING TO THE DRT CONNECTED M1 TO THE CONTRALATERAL DENTATE NUCLEUS VIA THE DENTATE-THALAMIC AREA, CLEARLY CROSSING THE MIDLINE IN THE MESENCEPHALON. GOOD RESPONSE WAS SEEN WHEN THE ACTIVE CONTACT VTA WAS IN THE THALAMIC AREA WITH HIGHEST CONNECTIVITY TO THE CONTRALATERAL DENTATE NUCLEUS. NON-RESPONDERS HAD ACTIVE CONTACT VTAS OUTSIDE THE DENTATE-THALAMIC AREA. WE CONCLUDE THAT PROBABILISTIC TRACTOGRAPHY TECHNIQUES CAN BE USED TO SEGMENT THE VL AND VP THALAMUS BASED ON CORTICAL AND CEREBELLAR CONNECTIVITY. THE THALAMIC AREA, BEST REPRESENTING THE VIM, IS CONNECTED TO THE CONTRALATERAL DENTATE CEREBELLAR NUCLEUS. CONNECTIVITY BASED SEGMENTATION OF THE VIM CAN BE ACHIEVED IN INDIVIDUAL PATIENTS IN A CLINICALLY FEASIBLE TIMESCALE, USING HARDI AND HIGH PERFORMANCE COMPUTING WITH PARALLEL GPU PROCESSING. THIS SAME TECHNIQUE CAN MAP OUT THE DRT TRACT WITH CLEAR MESENCEPHALIC CROSSING. REPORTED EVENTS: AN UNKNOWN AMOUNT OF PATIENTS HAD A POOR RESPONSE OR UNACCEPTABLE SIDE-EFFECTS DURING IMPLANT. IN THIS CASE, THE LEAD WAS REMOVED AND THE PROCESS WAS REPEATED FOLLOWING APPROPRIATE TARGETING ADJUSTMENTS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
263610 ACTIVA STIMULATOR, ELECTRICAL, IMPLANTED, FOR PARKINSONIAN TREMOR MHY MEDTRONIC NEUROMODULATION 3389 UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 64 YR